A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors

HIGHLIGHTS

• who: Walid Shalata and collaborators from the The Legacy Heritage Center and DrLarry Norton Institute, Soroka Medical Center and Ben Gurion University have published the research: A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors, in the Journal: Cancers 2022, 14, x FOR PEER REVIEW of /2022/
• what: The authors investigate current research on immune checkpoint inhibitors cutaneous adverse events and common presentations and treatments with specific focus on Bullous Pemphigoid its characteristics onset timing and treatment. The authors investigate the differences in timing of BP onset following . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.